Brain Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

CNS Tumor (517)

Medulloblastoma (29)

CNS Tumor (517)

Medulloblastoma (29)

›

MGMT unmethylation	Glioma	MGMT unmethylation	Glioma	temozolomide + interferon α-2b Sensitive: B - Late Trials JAMA Netw Open - 1 week (New B) temozolomide + interferon α-2b Sensitive : B JAMA Netw Open - 1wk	temozolomide + interferon α-2b Sensitive: B - Late Trials JAMA Netw Open - 1 week temozolomide + interferon α-2b Sensitive : B JAMA Netw Open - 1 week - (New B)
EGFR amplification	Glioblastoma	EGFR amplification	Glioblastoma	nivolumab + bevacizumab Resistant: C3 – Early Trials Cancer Immunol Immunother - 1 week (New C3) nivolumab + bevacizumab Resistant : C3 Cancer Immunol Immunother - 1wk	nivolumab + bevacizumab Resistant: C3 – Early Trials Cancer Immunol Immunother - 1 week nivolumab + bevacizumab Resistant : C3 Cancer Immunol Immunother - 1 week - (New C3)
PD-L1 overexpression	Glioblastoma	PD-L1 overexpression	Glioblastoma	nivolumab + bevacizumab Sensitive: C3 – Early Trials Cancer Immunol Immunother - 1 week (New C3) nivolumab + bevacizumab Sensitive : C3 Cancer Immunol Immunother - 1wk	nivolumab + bevacizumab Sensitive: C3 – Early Trials Cancer Immunol Immunother - 1 week nivolumab + bevacizumab Sensitive : C3 Cancer Immunol Immunother - 1 week - (New C3)
EGFR amplification	Glioblastoma	EGFR amplification	Glioblastoma	pembrolizumab + bevacizumab Resistant: C3 – Early Trials Cancer Immunol Immunother - 1 week (New C3) pembrolizumab + bevacizumab Resistant : C3 Cancer Immunol Immunother - 1wk	pembrolizumab + bevacizumab Resistant: C3 – Early Trials Cancer Immunol Immunother - 1 week pembrolizumab + bevacizumab Resistant : C3 Cancer Immunol Immunother - 1 week - (New C3)
PD-L1 overexpression	Glioblastoma	PD-L1 overexpression	Glioblastoma	pembrolizumab + bevacizumab Sensitive: C3 – Early Trials Cancer Immunol Immunother - 1 week (New C3) pembrolizumab + bevacizumab Sensitive : C3 Cancer Immunol Immunother - 1wk	pembrolizumab + bevacizumab Sensitive: C3 – Early Trials Cancer Immunol Immunother - 1 week pembrolizumab + bevacizumab Sensitive : C3 Cancer Immunol Immunother - 1 week - (New C3)
EGFR amplification	Glioblastoma	EGFR amplification	Glioblastoma	nivolumab Resistant: C3 – Early Trials Cancer Immunol Immunother - 1 week (New C3) nivolumab Resistant : C3 Cancer Immunol Immunother - 1wk	nivolumab Resistant: C3 – Early Trials Cancer Immunol Immunother - 1 week nivolumab Resistant : C3 Cancer Immunol Immunother - 1 week - (New C3)
PD-L1 overexpression	Glioblastoma	PD-L1 overexpression	Glioblastoma	nivolumab Sensitive: C3 – Early Trials Cancer Immunol Immunother - 1 week (New C3) nivolumab Sensitive : C3 Cancer Immunol Immunother - 1wk	nivolumab Sensitive: C3 – Early Trials Cancer Immunol Immunother - 1 week nivolumab Sensitive : C3 Cancer Immunol Immunother - 1 week - (New C3)
PD-L1 overexpression	Glioblastoma	PD-L1 overexpression	Glioblastoma	pembrolizumab Sensitive: C3 – Early Trials Cancer Immunol Immunother - 1 week (New C3) pembrolizumab Sensitive : C3 Cancer Immunol Immunother - 1wk	pembrolizumab Sensitive: C3 – Early Trials Cancer Immunol Immunother - 1 week pembrolizumab Sensitive : C3 Cancer Immunol Immunother - 1 week - (New C3)
EGFR amplification	Glioblastoma	EGFR amplification	Glioblastoma	pembrolizumab Resistant: C3 – Early Trials Cancer Immunol Immunother - 1 week (New C3) pembrolizumab Resistant : C3 Cancer Immunol Immunother - 1wk	pembrolizumab Resistant: C3 – Early Trials Cancer Immunol Immunother - 1 week pembrolizumab Resistant : C3 Cancer Immunol Immunother - 1 week - (New C3)
No biomarker	Glioblastoma	No biomarker	Glioblastoma	Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval Byvasda (bevacizumab biosimilar) Sensitive : A1	Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval Byvasda (bevacizumab biosimilar) Sensitive : A1
No biomarker	Brain Cancer	No biomarker	Brain Cancer	lomustine Sensitive: A1 - Approval lomustine Sensitive : A1	lomustine Sensitive: A1 - Approval lomustine Sensitive : A1
No biomarker	Astrocytoma	No biomarker	Astrocytoma	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1
No biomarker	Astrocytoma	No biomarker	Astrocytoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Ependymoma	No biomarker	Ependymoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Medulloblastoma	No biomarker	Medulloblastoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Anaplastic Astrocytoma	No biomarker	Anaplastic Astrocytoma	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
No biomarker	Glioma	No biomarker	Glioma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval Krabeva (bevacizumab biosimilar) Sensitive : A1	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval Krabeva (bevacizumab biosimilar) Sensitive : A1
No biomarker	Glioma	No biomarker	Glioma	teserpaturev Sensitive: A1 - Approval teserpaturev Sensitive : A1	teserpaturev Sensitive: A1 - Approval teserpaturev Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	bevacizumab-adcd Sensitive: A1 - Approval bevacizumab-adcd Sensitive : A1	bevacizumab-adcd Sensitive: A1 - Approval bevacizumab-adcd Sensitive : A1
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
BRAF V600E	Glioblastoma	BRAF V600E	Glioblastoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
No biomarker	Glioblastoma	No biomarker	Glioblastoma	PCV Sensitive: A2 - Guideline PCV Sensitive : A2	PCV Sensitive: A2 - Guideline PCV Sensitive : A2
No biomarker	Anaplastic Astrocytoma	No biomarker	Anaplastic Astrocytoma	PCV Sensitive: A2 - Guideline PCV Sensitive : A2	PCV Sensitive: A2 - Guideline PCV Sensitive : A2
No biomarker	Glioma	No biomarker	Glioma	PCV Sensitive: A2 - Guideline PCV Sensitive : A2	PCV Sensitive: A2 - Guideline PCV Sensitive : A2
MGMT promoter methylation	Glioblastoma	MGMT promoter methylation	Glioblastoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Glioma	No biomarker	Glioma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Meningioma	No biomarker	Meningioma	bevacizumab + everolimus Sensitive: A2 - Guideline bevacizumab + everolimus Sensitive : A2	bevacizumab + everolimus Sensitive: A2 - Guideline bevacizumab + everolimus Sensitive : A2
No biomarker	Meningioma	No biomarker	Meningioma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
No biomarker	Meningioma	No biomarker	Meningioma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Medulloblastoma	No biomarker	Medulloblastoma	cisplatin + cyclophosphamide + vincristine Sensitive: A2 - Guideline cisplatin + cyclophosphamide + vincristine Sensitive : A2	cisplatin + cyclophosphamide + vincristine Sensitive: A2 - Guideline cisplatin + cyclophosphamide + vincristine Sensitive : A2
No biomarker	Medulloblastoma	No biomarker	Medulloblastoma	cisplatin + vincristine + lomustine Sensitive: A2 - Guideline cisplatin + vincristine + lomustine Sensitive : A2	cisplatin + vincristine + lomustine Sensitive: A2 - Guideline cisplatin + vincristine + lomustine Sensitive : A2
BRAF V600E	Ganglioglioma	BRAF V600E	Ganglioglioma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
No biomarker	Glioma	No biomarker	Glioma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2

Brain Cancer

Associations(510)

Associations
(510)